AEON Biopharma, Inc.
AEON
$0.75
-$0.07-7.98%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.35M | 12.06M | 12.12M | 13.64M | 15.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.87M | 17.95M | 21.39M | 27.82M | 33.70M |
| Operating Income | -16.87M | -17.95M | -21.39M | -27.82M | -33.70M |
| Income Before Tax | -3.00K | -1.64M | 169.12M | 42.01M | 13.68M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 0.00 | -1.64 | 169.12 | 42.01 | 13.68 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.00K | -1.64M | 169.12M | 42.01M | 13.68M |
| EBIT | -16.87M | -17.95M | -21.39M | -27.82M | -33.70M |
| EBITDA | -16.79M | -17.87M | -21.30M | -27.73M | -33.60M |
| EPS Basic | 5.05 | -5.80 | 298.80 | 68.65 | 14.04 |
| Normalized Basic EPS | -4.65 | -9.37 | -7.85 | -74.34 | -72.69 |
| EPS Diluted | 4.76 | -6.09 | 298.51 | 68.35 | 14.04 |
| Normalized Diluted EPS | -4.64 | -9.36 | -7.83 | -74.33 | -72.69 |
| Average Basic Shares Outstanding | 27.26M | 16.18M | 5.63M | 2.16M | 2.12M |
| Average Diluted Shares Outstanding | 27.27M | 16.18M | 5.63M | 2.16M | 2.12M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |